Skip to main content
Erschienen in:

22.10.2019 | Knochenmetastasen | CME

Knochengesundheit bei Tumorpatienten

verfasst von: Leah T. Braun, Dr. Vanessa Pfahler, Dr. Ulla Stumpf, Dr. Montserrat Pazos Escudero, Prof. Dr. Nadia Harbeck, Prof. Dr. med. Ralf Schmidmaier, MME

Erschienen in: Die Onkologie | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Knochengesundheit bei Tumorpatienten spielt in der onkologischen Versorgung eine elementare Rolle. Knochenmetastasen gehören zu den häufigsten Metastasen und bedingen klinische Probleme wie Schmerzen, pathologische Frakturen und tumorinduzierte Hyperkalzämie (TIH). Wichtig ist zudem die therapiebedingte Osteoporose aufgrund der mit ihr einhergehenden Morbidität und Mortalität. Medikamentös kommen Antiresorptiva in unterschiedlicher Dosierung zum Einsatz. Bei frakturgefährdeten Knochen oder bereits eingetretener Fraktur kommen Strahlentherapie und Operation zur Anwendung. Die Komplexität der Knochengesundheit bei Tumorpatienten erfordert eine enge interdisziplinäre Zusammenarbeit zwischen Onkologen, Radiologen, Strahlentherapeuten, Chirurgen, Endokrinologen, Gynäkologen und anderen Spezialisten.
Literatur
2.
Zurück zum Zitat Raue F, Blind E (1993) Parathormon-related protein (PThrP): Ein neuer Tumormarker bei der Tumorhyperkalzämie. Dtsch Arztebl Int 90(51/52):3439–3441 Raue F, Blind E (1993) Parathormon-related protein (PThrP): Ein neuer Tumormarker bei der Tumorhyperkalzämie. Dtsch Arztebl Int 90(51/52):3439–3441
3.
Zurück zum Zitat Mirrakhimov AE (2015) Hypercalcemia of malignancy: an update on pathogenesis and management. North Am J Med Sci 7(11):483–493CrossRef Mirrakhimov AE (2015) Hypercalcemia of malignancy: an update on pathogenesis and management. North Am J Med Sci 7(11):483–493CrossRef
4.
Zurück zum Zitat Kloth JK, Wolf M, Rehnitz C, Lehner B, Wiedenhofer B, Weber MA (2012) Radiological diagnostics of spinal tumors. Part 1: general tumor diagnostics and special diagnostics of extradural tumors. Orthopäde 41(8):595–607CrossRef Kloth JK, Wolf M, Rehnitz C, Lehner B, Wiedenhofer B, Weber MA (2012) Radiological diagnostics of spinal tumors. Part 1: general tumor diagnostics and special diagnostics of extradural tumors. Orthopäde 41(8):595–607CrossRef
5.
Zurück zum Zitat Rodallec MH, Feydy A, Larousserie F, Anract P, Campagna R, Babinet A et al (2008) Diagnostic imaging of solitary tumors of the spine: what to do and say. Radiographics 28(4):1019–1041CrossRef Rodallec MH, Feydy A, Larousserie F, Anract P, Campagna R, Babinet A et al (2008) Diagnostic imaging of solitary tumors of the spine: what to do and say. Radiographics 28(4):1019–1041CrossRef
6.
Zurück zum Zitat Vogler JB 3rd, Murphy WA (1988) Bone marrow imaging. Radiology 168(3):679–693CrossRef Vogler JB 3rd, Murphy WA (1988) Bone marrow imaging. Radiology 168(3):679–693CrossRef
7.
Zurück zum Zitat Heindel W, Gübitz R, Vieth V, Weckesser M, Schober O, Schäfers M (2014) The diagnostic imaging of bone metastases. Dtsch Arztebl Int 111(44):741–747PubMedPubMedCentral Heindel W, Gübitz R, Vieth V, Weckesser M, Schober O, Schäfers M (2014) The diagnostic imaging of bone metastases. Dtsch Arztebl Int 111(44):741–747PubMedPubMedCentral
8.
Zurück zum Zitat Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2(3):201–209CrossRef Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2(3):201–209CrossRef
9.
Zurück zum Zitat Mantyh P (2013) Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 154(Suppl 1):S54–S62CrossRef Mantyh P (2013) Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 154(Suppl 1):S54–S62CrossRef
11.
Zurück zum Zitat Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ et al (2008) Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 14(20):6690–6696CrossRef Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ et al (2008) Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 14(20):6690–6696CrossRef
12.
Zurück zum Zitat Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139CrossRef Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139CrossRef
13.
Zurück zum Zitat Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G et al (2013) Efficacy and safety of 12-weekly versus 4‑weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663–670CrossRef Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G et al (2013) Efficacy and safety of 12-weekly versus 4‑weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663–670CrossRef
14.
Zurück zum Zitat Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J et al (2015) Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol 26(11):2205–2213CrossRef Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J et al (2015) Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol 26(11):2205–2213CrossRef
15.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353–1361CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353–1361CrossRef
16.
Zurück zum Zitat Thomas M, Schneider W (1989) Differentialdiagnose und Therapie tumorbedingter Hypercalcämien. Dtsch Med Wochenschr 114(41):1576–1581CrossRef Thomas M, Schneider W (1989) Differentialdiagnose und Therapie tumorbedingter Hypercalcämien. Dtsch Med Wochenschr 114(41):1576–1581CrossRef
17.
Zurück zum Zitat Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE et al (2017) Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol 7(1):4–12CrossRef Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE et al (2017) Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol 7(1):4–12CrossRef
18.
Zurück zum Zitat Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ et al (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366(9486):643–648CrossRef Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ et al (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366(9486):643–648CrossRef
19.
Zurück zum Zitat Nijs S, Broos P, Cutsem EV (2004) Treatment of a metastasis of a rectal carcinoma in the greater trochanter with the AO/ASIF proximal femoral nail. A case report. Acta Chir Belg 104(2):237–239CrossRef Nijs S, Broos P, Cutsem EV (2004) Treatment of a metastasis of a rectal carcinoma in the greater trochanter with the AO/ASIF proximal femoral nail. A case report. Acta Chir Belg 104(2):237–239CrossRef
20.
Zurück zum Zitat Mirels H (2003) Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res 415:S4–S13CrossRef Mirels H (2003) Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res 415:S4–S13CrossRef
21.
Zurück zum Zitat Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH et al (2010) A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine 35(22):E1221–E1229CrossRef Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH et al (2010) A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine 35(22):E1221–E1229CrossRef
22.
Zurück zum Zitat Fourney DR, Frangou EM, Ryken TC, Dipaola CP, Shaffrey CI, Berven SH et al (2011) Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29(22):3072–3077CrossRef Fourney DR, Frangou EM, Ryken TC, Dipaola CP, Shaffrey CI, Berven SH et al (2011) Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29(22):3072–3077CrossRef
23.
Zurück zum Zitat Dohm M, Black CM, Dacre A, Tillman JB, Fueredi G (2014) A randomized trial comparing balloon kyphoplasty and vertebroplasty for vertebral compression fractures due to osteoporosis. AJNR Am J Neuroradiol 35(12):2227–2236CrossRef Dohm M, Black CM, Dacre A, Tillman JB, Fueredi G (2014) A randomized trial comparing balloon kyphoplasty and vertebroplasty for vertebral compression fractures due to osteoporosis. AJNR Am J Neuroradiol 35(12):2227–2236CrossRef
24.
Zurück zum Zitat Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRef Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRef
25.
Zurück zum Zitat Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82(4):288–292CrossRef Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82(4):288–292CrossRef
26.
Zurück zum Zitat Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B et al (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152(6):380–390CrossRef Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B et al (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152(6):380–390CrossRef
27.
Zurück zum Zitat Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P (2016) The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat 155(1):151–157CrossRef Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P (2016) The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat 155(1):151–157CrossRef
28.
Zurück zum Zitat Waning DL, Guise TA (2015) Cancer-associated muscle weakness: What’s bone got to do with it? Bonekey Rep 4:691CrossRef Waning DL, Guise TA (2015) Cancer-associated muscle weakness: What’s bone got to do with it? Bonekey Rep 4:691CrossRef
30.
Zurück zum Zitat Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR (2000) Recognition of vertebral fracture in a clinical setting. Osteoporos Int 11(7):577–582CrossRef Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR (2000) Recognition of vertebral fracture in a clinical setting. Osteoporos Int 11(7):577–582CrossRef
31.
Zurück zum Zitat Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C et al (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 7:Cd333 Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C et al (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 7:Cd333
Metadaten
Titel
Knochengesundheit bei Tumorpatienten
verfasst von
Leah T. Braun
Dr. Vanessa Pfahler
Dr. Ulla Stumpf
Dr. Montserrat Pazos Escudero
Prof. Dr. Nadia Harbeck
Prof. Dr. med. Ralf Schmidmaier, MME
Publikationsdatum
22.10.2019
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 12/2019
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-019-00663-y

Weitere Artikel der Ausgabe 12/2019

Die Onkologie 12/2019 Zur Ausgabe